Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function

S. A. Long, M. Rieck, S. Sanda, J. B. Bollyky, P. L. Samuels, R. Goland, A. Ahmann, A. Rabinovitch, S. Aggarwal, D. Phippard, L. A. Turka, M. R. Ehlers, P. J. Bianchine, K. D. Boyle, S. A. Adah, J. A. Bluestone, J. H. Buckner, C. J. Greenbaum

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)S91
JournalDiabetes Technology and Therapeutics
Volume15
Issue numberSUPPL.1
DOIs
StatePublished - Jun 1 2013

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Medical Laboratory Technology

Cite this

Long, S. A., Rieck, M., Sanda, S., Bollyky, J. B., Samuels, P. L., Goland, R., Ahmann, A., Rabinovitch, A., Aggarwal, S., Phippard, D., Turka, L. A., Ehlers, M. R., Bianchine, P. J., Boyle, K. D., Adah, S. A., Bluestone, J. A., Buckner, J. H., & Greenbaum, C. J. (2013). Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes Technology and Therapeutics, 15(SUPPL.1), S91. https://doi.org/10.1089/dia.2013.1510